Please assess the completion status of the following clinical trial:

Trial Title: Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female, 18 years of age or older~* Histologically confirmed HER2-positive metastatic breast cancer~* Trastuzumab-resistance~* Measurable disease, according to RECIST guidelines~* ECOG performance status less than or equal to 1~* Life expectancy greater than 3 months~* No prior treatment with temsirolimus, everolimus, rapamycin, or any other mTOR inhibitor~* At least 4 weeks must have lapsed between prior investigational therapy, chemotherapy or radiotherapy, and the first dose of ridaforolimus~* Left ventricular ejection greater than or equal to 50%~* Adequate cardiovascular function~* Adequate hematological, hepatic, and renal function~* Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal to 400 mg/dL~* Negative pregnancy test within 7 days prior to first dose of study drug and must use an approved contraceptive method from screening to 30 days after the last dose of study drug~* Availability and patient consent to obtain archival tissue samples~* Signed informed consent~Exclusion Criteria:~* Inadequate recovery from any prior surgical procedure or having undergone any major surgery within 2 weeks before trial entry~* Grade 1 or Grade 2 hypersensitivity reactions to prior trastuzumab therapy if these reactions prevented further trastuzumab administration~* Grade 3 or Grade 4 hypersensitivity reaction to prior trastuzumab~* Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest~* Known allergy to macrolide antibiotics~* Pregnant or breast-feeding~* Know history of HIV~* Diagnosis of brain metastasis or leptomeningeal carcinomatosis within 3 months~* Other malignancies within the past 3 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin~* Active infection requiring prescription intervention~* Newly diagnosed or poorly controlled Type 1 or 2 diabetes~* Other concurrent illness which, in the Investigator's judgment, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug~* Concurrent treatment with medications that strongly induce or inhibit cytochrome P450.~* Any condition that renders patient unable to fully understand and provide informed consent and/or comply with the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).